The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
motexafin gadolinium (MGd)
Motexafin gadolinium (MGd) is a type of metalloporphyrin complex also called gadolinium texaphyrin with a novel
mechanism of action; it accumulates selectively in cancer cells due to
their increased rates of metabolism. Once inside the cell, MGd induces
apoptosis (programmed cell death) by disrupting redox-dependent
pathways. MGd inhibits the enzyme thioredoxin reductase, which is a
tumor growth promoter. This mechanism provides the opportunity to use
MGd in a wide range of cancers. MGd is paramagnetic, and therefore is
detectable by magnetic resonance imaging (MRI), allowing the
visualization of the drug in tumors.